Abstract
Background
Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results.
Methods
We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes.
Results
Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Qmax) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups.
Conclusion
PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.






Similar content being viewed by others
Abbreviations
- PUL:
-
Prostatic urethral lift
- BPH:
-
Benign prostatic hyperplasia
- LUTS:
-
Lower urinary tract symptoms
- TURP:
-
Transurethral resection of prostate
- TUNA:
-
Transurethral needle ablation
- TUMT:
-
Transurethral microwave thermotherapy
- IPSS:
-
International prostate symptom score
- Qmax:
-
Peak flow rate
- PVR:
-
Post-void residual
- QOL:
-
Quality of life
- MSHQ-EjD:
-
Male Sexual Health Questionnaire for Ejaculatory Dysfunction
- MSHQ-Bother:
-
Male Sexual Health Questionnaire for Ejaculation bother
References
St Sauver JL, Jacobson DJ, Girman CJ, Lieber MM, McGree ME, Jacobsen SJ (2006) Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 175(3 Pt 1):1018–1022. https://doi.org/10.1016/s0022-5347(05)00408-8(discussion 980)
Ally M, Lee T, Ecclestone H, Teo L, Kavia R (2017) Malignant features of a benign waiting list. J Clin Urol 10(2):105–109
Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin 95(1):87–100
Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 44(5):539–545. https://doi.org/10.1016/s0302-2838(03)00376-2
Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50(5):969–979. https://doi.org/10.1016/j.eururo.2005.12.042(discussion 980)
Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, Stief CG, Woo HH, Gratzke C (2017) Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol 72(6):986–997. https://doi.org/10.1016/j.eururo.2017.07.005
Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, Somani BK (2016) Medium-term outcomes of urolift (Minimum 12 Months Follow-up): evidence from a systematic review. Urology 97:20–24. https://doi.org/10.1016/j.urology.2016.05.003
Magistro G, Stief CG, Woo HH (2018) Mini-review: what is new in urolift? Eur Urol Focus 4(1):36–39. https://doi.org/10.1016/j.euf.2018.01.013
Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC, Roehrborn CG (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82–88. https://doi.org/10.1111/j.1464-410X.2011.10342.x
Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, Roehrborn CG, Woo HH (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5–11. https://doi.org/10.1016/j.urology.2011.10.021
McNicholas TA, Woo HH, Chin PT, Bolton D, Fernandez Arjona M, Sievert KD, Schoenthaler M, Wetterauer U, Vrijhof EJ, Gange S, Montorsi F (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292–299. https://doi.org/10.1016/j.eururo.2013.01.008
Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P (2015) Three year results of the prostatic urethral LIFT study. Can J Urol 22(3):7772–7782
Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB (2017) Five year results of the prospective randomized controlled prostatic urethral LIFT study. Can J Urol 24(3):8802–8813
Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, Chin PT, Woo HH (2014) Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113(4):615–622. https://doi.org/10.1111/bju.12540
Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643–652. https://doi.org/10.1016/j.eururo.2015.04.024
Bozkurt A, Karabakan M, Keskin E, Hirik E, Balci MB, Nuhoglu B (2016) Prostatic urethral lift: a new minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol Int 96(2):202–206. https://doi.org/10.1159/000441850
Gratzke C, Barber N, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Patterson JM, Fahrenkrug L, Schoenthaler M, Sonksen J (2017) Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int 119(5):767–775. https://doi.org/10.1111/bju.13714
Rukstalis D, Rashid P, Bogache WK, Tutrone RF, Barkin J, Chin PT, Woo HH, Cantwell AL, Cowan BE, Bolton DM (2016) 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. BJU Int 118(Suppl 3):14–22. https://doi.org/10.1111/bju.13666
Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P (2018) Prostatic urethral lift: does size matter? J Endourol 32(7):635–638. https://doi.org/10.1089/end.2017.0855
Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, Miller F, Wetterauer U, Volkmer B, Gratzke C, Amend B (2019) Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol 37(7):1353–1360. https://doi.org/10.1007/s00345-018-2494-1
Garcia C, Chin P, Rashid P, Woo HH (2015) Prostatic urethral lift: a minimally invasive treatment for benign prostatic hyperplasia. Prostate Int 3(1):1–5. https://doi.org/10.1016/j.prnil.2015.02.002
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100
Deeks JJ, Higgins JP, Altman DG (2008) Analysing data and undertaking meta‐analyses. Cochrane Handb Syst Rev Interv, pp 241–284
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148(5):1549–1557. https://doi.org/10.1016/s0022-5347(17)36966-5(discussion 1564)
Rosen RC, Catania J, Pollack L, Althof S, O'Leary M, Seftel AD (2004) Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology 64(4):777–782. https://doi.org/10.1016/j.urology.2004.04.056
Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM et al. (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898 https://doi.org/10.1136/bmj.l4898
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:4919
McGuinness LA (2019) Robvis: an R package and web application for visualising risk-of-bias assessments. https://github.com/mcguinlu/robvis
von Hippel PT (2015) The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol 15:35. https://doi.org/10.1186/s12874-015-0024-z
Strope SA, Vetter J, Elliott S, Andriole GL, Olsen MA (2015) Use of medical therapy and success of laser surgery and transurethral resection of the prostate for benign prostatic hyperplasia. Urology 86(6):1115–1122. https://doi.org/10.1016/j.urology.2015.07.019
Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM (2006) Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 6:14. https://doi.org/10.1186/1471-2490-6-14
Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ (2012) Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004135.pub3
Eure G, Gange S, Walter P, Khan A, Chabert C, Mueller T, Cozzi P, Patel M, Freedman S, Chin P, Ochs S, Hirsh A, Trotter M, Grier D (2019) Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. J Endourol 33(7):576–584. https://doi.org/10.1089/end.2019.0167
Jung JH, Reddy B, McCutcheon KA, Borofsky M, Narayan V, Kim MH, Dahm P (2019) Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 5:Cd012832. https://doi.org/10.1002/14651858.CD012832.pub2
US Department of Health and Human Services CfMaMSPBNSDF (2016) https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Part-B-National-Summary-Data-File/Overview.html.
Author information
Authors and Affiliations
Contributions
TK: project development, data collection, and manuscript writing. GS: data collection and data analysis. ND: data collection and data analysis. KJ: manuscript writing. MA: manuscript writing. SK: manuscript review and editing. BK: data review, manuscript review, and editing. CJ: data review, manuscript review, and editing.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
Ethic approval is not required because this is a protocol for a systematic review and meta-analysis in which no primary human data will be collected.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tanneru, K., Gautam, S., Norez, D. et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. Int Urol Nephrol 52, 999–1008 (2020). https://doi.org/10.1007/s11255-020-02408-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-020-02408-y


